Shaily Engineering Plastics Limited has informed the Exchange about Investor Presentation
SHAILY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shaily Engineering Plastics filed its Q4 & FY25 investor presentation ahead of the earnings call. Consolidated FY25 revenue grew 22% YoY to Rs. 786.8 Cr, with EBITDA up 45% to Rs. 178.4 Cr and EBITDA margin expanding 350 bps to 22.7%. PAT jumped 63% to Rs. 93.1 Cr. Q4 FY25 was even stronger, with revenue of Rs. 217.8 Cr (+28% YoY) and EBITDA margin at 25.1% (+380 bps). The Healthcare segment led growth, with Q4 revenue up 45% YoY to Rs. 56 Cr, driven by commercial supply commitments for GLP-1 drug Semaglutide starting in FY26 and six new pen injector contracts. Returns improved sharply — RoCE rose to 24.4% and RoE to 18.5%, while debt-to-equity eased to 1.48x from 1.71x.
This is a strong operational and financial performance update that should be viewed positively by shareholders. Sharp margin expansion, rising return ratios, a robust healthcare order pipeline (GLP-1 pen injectors, capacity expansion), and a credit rating upgrade to CARE A+ collectively signal improving business quality and growth visibility, which are likely to support investor sentiment and the stock price.